Article ; Online: Preventive Treatment of Migraine.
Continuum (Minneapolis, Minn.)
2024 Volume 30, Issue 2, Page(s) 364–378
Abstract: Objective: This article describes strategies for the preventive treatment of migraine including the emerging role of calcitonin gene-related peptide (CGRP)-targeted therapies and introduces novel paradigms for the preventive treatment of migraine.: ... ...
Abstract | Objective: This article describes strategies for the preventive treatment of migraine including the emerging role of calcitonin gene-related peptide (CGRP)-targeted therapies and introduces novel paradigms for the preventive treatment of migraine. Latest developments: Multiple migraine medications targeting CGRP have been introduced since 2018, including injectable monoclonal antibodies (ie, eptinezumab, erenumab, fremanezumab, and galcanezumab) and oral small-molecule CGRP receptor antagonists (ie, ubrogepant, rimegepant, atogepant, and zavegepant). With the exceptions of ubrogepant and zavegepant, which are approved only as acute treatments, all of these agents have demonstrated efficacy in the preventive treatment of migraine; the monoclonal antibodies and atogepant have evidence of effectiveness in adults with either episodic or chronic migraine. The safety and tolerability profiles of CGRP-targeted therapies in migraine are favorable. Essential points: The goals of preventive migraine therapy include reducing the frequency, severity, duration, and disability associated with attacks, reducing the need for acute treatment and the risk of medication overuse, enhancing self-efficacy and health-related quality of life, and reducing headache-related distress and interictal burden. Six drugs targeting CGRP (four monoclonal antibodies and two gepants) are now available for the preventive treatment of episodic migraine in adults. The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment. |
---|---|
MeSH term(s) | Adult ; Humans ; Calcitonin Gene-Related Peptide ; Quality of Life ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Antibodies, Monoclonal/therapeutic use ; Piperidines ; Pyridines ; Pyrroles ; Spiro Compounds |
Chemical Substances | atogepant (7CRV8RR151) ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z) ; Antibodies, Monoclonal ; Piperidines ; Pyridines ; Pyrroles ; Spiro Compounds |
Language | English |
Publishing date | 2024-04-03 |
Publishing country | United States |
Document type | Journal Article |
ISSN | 1538-6899 |
ISSN (online) | 1538-6899 |
DOI | 10.1212/CON.0000000000001418 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.